Welcome to our dedicated page for Vivos SEC filings (Ticker: RDGL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Vivos Inc. filings document formal disclosures for a radiotherapeutic company developing RadioGel® for human applications and IsoPet® for veterinary use. The company’s 8-K reports record material definitive agreements, executive appointments, compensatory arrangements, and governance changes tied to its operating structure.
Regulatory filings also frame RDGL’s public-company disclosures around capital structure, shareholder voting matters, clinical and regulatory updates, and operating and financial results. These records provide the formal context for the company’s radionuclide therapy programs, manufacturing and development activities, and corporate governance matters.
Vivos Inc. reported a larger quarterly loss while modestly growing early revenue as it develops its radionuclide cancer therapies. For the three months ended March 31, 2026, revenue was $36,068, up from $26,748, mainly from IsoPet® animal treatments and related products.
The company recorded a net loss of $1,184,845 versus $834,696 a year earlier, driven by operating expenses and a $651,628 loss on a warrant exchange. Cash was $2,525,782 with negative operating cash flow of $429,861. Management states there is substantial doubt about Vivos’ ability to continue as a going concern and estimates it needs about $3.0 million per year, or $9.0 million over 36 months, to fund planned activities.
To address this, Vivos continues to raise capital under its qualified Regulation A+ offerings, including new shares and warrants sold in March and April 2026. The company is advancing its IsoPet® veterinary business, pursuing FDA approval for RadioGel® human use, and building U.S. and Indian manufacturing and clinical infrastructure.
Vivos Inc CEO and President Michael K. Korenko, who also serves as a director, reported an open-market purchase of common stock. On May 11, 2026, he bought 150,000 shares of Vivos Inc common stock at $0.0618 per share. Following this transaction, his direct ownership increased to 11,085,090 common shares, indicating a modest addition to an already large personal stake in the company.
Vivos Inc
Vivos Inc. (RDGL) is a development‑stage radiation oncology device company focused on its Y‑90–based RadioGel® for humans and IsoPet® for animals. It reported strong operational traction in veterinary oncology, including a 1,200% year‑over‑year increase in IsoPet® therapies from 2024 to 2025, more than 100 treatments with zero reportable serious adverse events, and 17 certified clinics across the U.S. as of December 31, 2025.
To support growth and regulatory progress, Vivos is building a multi‑site manufacturing network, adding a domestic facility at the Applied Process Engineering Laboratory in Washington and pursuing an international site in India through its new subsidiary Vivos Scientific India LLP, which also advances human and animal trials there. The company strengthened its intellectual property with new patents and trademarks, including U.S. Patent No. 12,521,452 B2 protecting its hydrogel‑based Precision Radionuclide Therapy™ platform, and continues preparing an FDA Investigational Device Exemption resubmission for RadioGel® with guidance from a specialized regulatory expert.
Financially, Vivos remains highly dependent on external capital. It had $1,558,525 in cash at December 31, 2025, an accumulated deficit of $88,427,246, and net losses of $3,066,017 in 2025, and its auditors expressed substantial doubt about its ability to continue as a going concern. The company estimates it needs about $3.0 million per year, or $9.0 million over 36 months, to fund operations, FDA processes, initial clinical trials, clinic activation, and manufacturing build‑out, and is relying heavily on successive Regulation A+ equity offerings and potential partnerships to proceed.
Vivos Inc reported an insider share purchase by its CEO and President, who is also a director. On 12/31/2025, the reporting person acquired 200,000 shares of common stock in an open-market purchase at a price of $0.0646 per share, as shown by transaction code "P" for a purchase. Following this transaction, the insider beneficially owns 10,935,090 common shares, held directly.
Vivos Inc. reported an insider share purchase by its CEO, President, and Director, Michael Korenko. On 12/02/2025, he bought 100,000 shares of Vivos Inc. common stock in an open-market transaction coded "P" at a price of $0.0722 per share. Following this transaction, he beneficially owns 10,735,090 shares of common stock in direct ownership.
Vivos Inc. (RDGL) reported an insider share purchase by its CEO and President, who is also a director. On 11/20/2025, the reporting person bought 100,000 shares of Vivos Inc. common stock in an open-market transaction coded "P" at a price of $0.0622 per share.
Following this transaction, the insider now beneficially owns 10,635,090 shares of Vivos Inc. common stock held directly.
Vivos Inc (RDGL) reported Q3 2025 results. For the nine months ended September 30, 2025, revenue was $43,627 versus $23,000 a year ago, while Q3 revenue was $1,879 versus $5,000. The company posted a nine‑month operating loss of $2,069,328 and a net loss of $1,987,503.
Cash was $2,202,109 as of September 30, 2025. Operating cash use totaled $1,518,189 for the period, partially offset by $1,507,750 from financing activities, including $1,506,250 raised via a Regulation A+ equity issuance and related warrants. Shares outstanding were 454,664,957 as of November 11, 2025.
Management disclosed substantial doubt about the company’s ability to continue as a going concern and estimates it requires approximately $3.0 million annually to maintain operations and about $9.0 million over 36 months for clinical and commercialization plans. The Board approved Vivos Scientific India LLP on September 17, 2025, established October 1, 2025, to support manufacturing and human therapy initiatives.